The estimated Net Worth of Marco Taglietti is at least $1.37 Millón dollars as of 26 April 2022. Dr Taglietti owns over 75,000 units of Scynexis Inc stock worth over $380,895 and over the last 10 years he sold SCYX stock worth over $0. In addition, he makes $991,270 as CEO y Pres & Director at Scynexis Inc.
Sign up
Dr Taglietti SCYX stock SEC Form 4 insiders trading
Dr has made over 28 trades of the Scynexis Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 75,000 units of SCYX stock worth $225,000 on 26 April 2022.
The largest trade he's ever made was buying 200,000 units of Scynexis Inc stock on 27 July 2015 worth over $106,000. On average, Dr trades about 24,008 units every 48 days since 2014. As of 26 April 2022 he still owns at least 272,068 units of Scynexis Inc stock.
You can see the complete history of Dr Taglietti stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Marco Taglietti biography
Dr. Marco Taglietti is the CEO, Pres & Director at Scynexis Inc.
What is the salary of Dr Taglietti?
As the CEO y Pres & Director of Scynexis Inc, the total compensation of Dr Taglietti at Scynexis Inc is $991,270. There are no executives at Scynexis Inc getting paid more.
How old is Dr Taglietti?
Dr Taglietti is 60, he's been the CEO y Pres & Director of Scynexis Inc since . There are 7 older and 7 younger executives at Scynexis Inc. The oldest executive at Scynexis Inc is Patrick Langlois, 70, who is the Director.
What's Dr Taglietti's mailing address?
Marco's mailing address filed with the SEC is C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN, NJ, 07059.
Insiders trading at Scynexis Inc
Over the last 11 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado y Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
What does Scynexis Inc do?
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
What does Scynexis Inc's logo look like?
Complete history of Dr Taglietti stock trades at Scynexis Inc, Aquestive Therapeutics Inc y Delcath Systems
Scynexis Inc executives and stock owners
Scynexis Inc executives and other stock owners filed with the SEC include:
-
Dr. Marco Taglietti M.D.,
CEO, Pres & Director -
Dr. Marco Taglietti,
CEO, Pres & Director -
David Gonzalez Angulo,
Chief Medical Officer -
Eric Francois,
Chief Financial Officer -
Christine R. Coyne M.B.A.,
Chief Commercial Officer -
Philippe Tinmouth,
Director -
Jean-Yves Nothias,
Director -
Guy Macdonald,
Director -
Patrick Langlois,
Director -
David Hastings,
Director -
Ann Hanham,
Director -
Steven Gilman,
Director -
Laurent Arthaud,
Director -
Armando Anido,
Director -
David Angulo,
Chief Medical Officer -
Scott Sukenick,
General Counsel -
Nkechi Azie,
Vice President - Clinical Development -
Jim Maffezzoli,
Vice President of Sales and Marketing -
Eric Francois,
Chief Financial Officer -
Marco Taglietti,
President, Chief Executive Officer, Director -
Pamela Kirby,
Chairman of the Board -
Debbie Etchison,
Exec. Director of Communications -
Lawrence R. Hoffman CPA, Esq.,
Interim CFO & Principal Accounting Officer -
Dr. Rajeshwar Motheram,
Sr. VP of Pharmaceutical Devel. & Supply Chain -
Scott Sukenick J.D.,
Gen. Counsel & Corp. Sec. -
Patrick Machado,
Director -
Marion Mc Court,
Director -
Jr. Charles F Osborne,,
Chief Financial Officer -
Biopharma Partners Ii Lpalt...,
-
Carole Sable,
Chief Medical Officer -
Capital Ii Ventech,
10% owner -
Biotechnology Fund Fcpr,
10% owner -
Eileen Pruette,
General Counsel -
Genavent F.C.P.R.,
10% owner -
Mounia Chaoui,
Director -
Edward Penhoet,
Director -
Yves J Ribeill,
President and CEO -
Advisors Llcperceptive Life...,
-
Christine Coyne,
Chief Commercial Officer -
Ivor Macleod,
Chief Financial Officer